Elicio Therapeutics (FRA:9HA) Short-Term Capital Lease Obligation : €0.86 Mil (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Elicio Therapeutics Short-Term Capital Lease Obligation?

Elicio Therapeutics's Short-Term Capital Lease Obligation for the quarter that ended in Dec. 2024 was €0.86 Mil.

Elicio Therapeutics's quarterly Short-Term Capital Lease Obligation declined from Jun. 2024 (€0.79 Mil) to Sep. 2024 (€0.79 Mil) but then increased from Sep. 2024 (€0.79 Mil) to Dec. 2024 (€0.86 Mil).

Elicio Therapeutics's annual Short-Term Capital Lease Obligation increased from Dec. 2022 (€0.65 Mil) to Dec. 2023 (€0.83 Mil) and increased from Dec. 2023 (€0.83 Mil) to Dec. 2024 (€0.86 Mil).

Elicio Therapeutics Short-Term Capital Lease Obligation Historical Data

The historical data trend for Elicio Therapeutics's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elicio Therapeutics Short-Term Capital Lease Obligation Chart

Elicio Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.36

0.65

0.83

0.86

Elicio Therapeutics Quarterly Data
	Dec19	Mar20	Dec20	Mar21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial											0.83	0.81	0.79	0.79	0.86

Elicio Therapeutics Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Elicio Therapeutics Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Elicio Therapeutics's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Elicio Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Elicio Therapeutics Inc (FRA:9HA) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

ELTX:USA

Address

451 D Street, 5th Floor, Boston, MA, USA, 02210

Website

https://www.elicio.com

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.

Elicio Therapeutics Headlines

No Headlines